ライフサイエンスコーパス: cord blood

1 increase in the ratio of %-5mC to %-5hmC in cord blood.

2 n assessed from the mercury concentration in cord blood.

3 s an inhibitor of NET formation in umbilical cord blood.

4 nd primary mast cells derived from umbilical cord blood.

5 Ig-usage pattern comparable to B-1 cells in cord blood.

6 pression that more closely resembles that of cord blood.

7 cells has a regulatory cell phenotype in the cord blood.

8 y (12-16 wk), at delivery (28-42 wk), and in cord blood.

9 ide in hypoxic niches within bone marrow and cord blood.

10 irculate in healthy donors and are absent in cord blood.

11 and exists at very low levels in unexpanded cord blood.

12 encing (30 AGA, 21 SGA) and also analyzed in cord blood.

13 ethylated in placenta and hypermethylated in cord blood.

14 e were significantly higher in maternal than cord blood.

15 404 allogeneic HCT recipients, including 125 cord blood, 125 HLA-mismatched, and 154 HLA-matched HCTs

16 Prenatal and cord blood 25(OH)D levels were associated with some alle

17 At birth, median cord blood %-5mC, %-5hmC, and their ratio were 4.95%, 0.

18 in regulation of imprinting in placenta and cord blood; a lack of correlation of the methylome, tran

19 ons between maternal PFAS concentrations and cord blood adipocytokine concentrations were of small ma

20 We identified 1485 cord blood and 1708 placenta methylation variable positi

21 ata of 356 healthy individuals, including 47 cord blood and 28 bone marrow samples.

22 8 was 99.4%, 74.9%, 26.2%, 8.0%, and 1.6% in cord blood and 52.5%, 25.8%, 3.6%, 1.4%, and 0% at age 4

23 in the adult bone marrow and can be found in cord blood and adult peripheral blood.

24 Cord blood and age-14 serum were available for a subgrou

25 ct biological specimens, including umbilical cord blood and amniotic fluid, to be made available to t

26 y estimated from DNA methylation of neonatal cord blood and blood spot samples.

27 These progenitors reside in human cord blood and bone marrow but not in the blood or lymph

28 ors of human B-1 and B-2 cells, we separated cord blood and bone marrow Lin(-)CD34(+) hematopoietic s

29 polyomaviruses ranged from 38.5% to 99.8% in cord blood and from 20.9% to 82.3% at age 4.

30 n the field of alternative donors, including cord blood and haploidentical donors, are highlighted, a

31 onor registries and increased utilization of cord blood and partially matched related donor transplan

32 We obtained DNA methylation profiles from cord blood and peripheral blood at ages 7 and 17 in the

33 ormal karyotype compared with normal CD19(+) cord blood and peripheral blood B cells.

34 iferation, we compared the miRNA profiles of cord blood and peripheral blood ECFC-derived cells.

35 enotype and DNA methylation (DNAm) data from cord blood and peripheral blood to identify SNPs associa

36 ify genome-wide DNA methylation variation in cord blood and placenta from offspring born to mothers w

37 In distributed lag models, both cord blood and placental telomere length were associated

38 In 641 newborns, cord blood and placental telomere length were significan

39 with newborn telomere length as reflected by cord blood and placental telomere length.

40 nalysis, participants with full data on both cord blood and placental telomere lengths were included,

41 In the newborns, cord blood and placental tissue relative telomere length

42 associated with higher leptin levels in both cord blood and post-delivery maternal serum.

43 tion levels at 482,397 CpG loci in umbilical cord blood and retained 394,460 loci after quality contr

44 ent required the presence of CD4+ T cells in cord blood and was inhibited by CD40-blocking Abs.

45 xposure during midgestation (weeks 12-25 for cord blood and weeks 15-27 for placenta).

46 red in blood cell samples obtained at birth (cord blood) and ages 1 and 3 years.

47 ured in stored blood samples from pregnancy, cord blood, and age 2 years.

48 25[OH]D) levels in mothers during pregnancy, cord blood, and children at school age (median age, 7.7

49 nd serum 25(OH)D levels in pregnant mothers, cord blood, and children at school age were weak to mode

50 centa and levels of its ligands in umbilical cord blood, and to verify the influence of Cxcr3 on SPTB

51 The CpG targets of ASD meQTLs across cord, blood, and brain tissues are enriched for immune-r

52 Human cord blood-and peripheral blood-derived mast cells were

53 Geometric mean concentrations (GMCs) of cord blood antibodies to recombinant pertussis toxin (PT

54 r clinical use is restricted because HSCs in cord blood are found only in small numbers.

55 true numbers of HSCs in the bone marrow and cord blood are routinely underestimated.

56 titution, especially when HSC from umbilical cord blood are used.

57 nce available to strongly support the use of cord blood as a strategic platform for a broader applica

58 y associated with maternal and GPx levels in cord blood as well as maternal TNF-alpha levels were inv

59 at enrollment, at 36 wk of gestation, and in cord blood at birth.

60 at glucocorticoids are lower in maternal and cord blood at delivery in obese pregnancies.

61 regnancy have been described in placenta and cord blood at delivery, in fetal lung, and in buccal epi

62 We collected maternal and cord blood at delivery, measured manganese using inducti

63 enatal lead exposure with DNA methylation in cord blood at epigenome-wide significance level [false d

64 expressed a VH-DH-JH composition similar to cord blood B-1 cells, including frequent use of VH4-34 (

65 lergic disease at 18 months of age had lower cord blood BAFF levels than nonallergic children.

66 rapid selection and release of CBUs from the cord blood bank to the transplant center for transplanta

67 ences between HSCs derived from fetal liver, cord blood, bone marrow, and peripheral blood.

68 study, we examine whether DNA methylation in cord blood can be used to estimate gestational age at bi

69 flected by soluble inflammatory mediators in cord blood, can condition an individual's susceptibility

70 tation (CBT), due in part to a defect in the cord blood (CB) cells' ability to home to the bone marro

71 yping of recipient germline and transplanted cord blood (CB) grafts predicted for large differences i

72 Human umbilical cord blood (CB) has attracted much attention as a reserv

73 the continued controversy regarding whether cord blood (CB) IgE originates in the mother or fetus.

74 Cord blood (CB) offers a number of advantages over other

75 hils is faster in recipients of the modified cord blood (CB) unit when compared with historical contr

76 en HSC numbers are limited, as in the use of cord blood (CB).

77 that LC and iDDC generated from pluripotent cord blood CD34(+) cell precursors support productive in

78 A small subset of human cord blood CD34(+) cells express endothelial protein C r

79 lity improve the expansion capacity of human cord blood CD34(+) cells in the absence of exogenous cyt

80 Knockdown of ASXL1 in cord blood CD34(+) cells reduced erythropoiesis and impa

81 n compared with repopulation-competent human cord blood CD34(+) cells, indicating incorrect mesoderm

82 s greater in AML blasts compared with normal cord blood CD34(+) cells.

83 mental model system was employed using human cord blood CD34(+) hematopoietic stem/progenitor cells.

84 e engineering of primary adult and umbilical cord blood CD34(+) human hematopoietic stem and progenit

85 Specific selection of human cord blood CD34(+)CD38(-)CD45RA(-)lin(-) PTPsigma(-) cel

86 Neonatal and human cord blood CD71(+) cells express arginase II, and this e

87 r of six HLA-matched CCR5 Delta32 homozygous cord blood cells (StemCyte, Covina, CA), supported with

88 IR/HLA genetic incompatibilities and studied cord blood cells at both the phenotypic and functional l

89 and cell-cycle indicators in single CD34(+) cord blood cells before and up to 2 hours after their st

90 It is interesting to note that cord blood cells exhibited extremely low HLA class I exp

91 AE immortalizes human CD34(+) cord blood cells in long-term culture.

92 and that expression of mutant WT1 in CD34(+) cord blood cells induced myeloid differentiation block.

93 t human iTregs generated in vitro from naive cord blood cells preferentially recruit Disc large homol

94 rming in a murine retroviral model, in human cord blood cells.

95 3/ITD(neg) cells and spared normal umbilical cord blood cells.

96 nd CD8(+) effector and memory T cells in the cord blood compared with controls.

97 nes were assessed for their association with cord blood concentrations of folate and UMFA.

98 rospective study, we determined maternal and cord blood concentrations of folate and unmetabolized fo

99 sma PFAS concentrations and birth weight and cord blood concentrations of leptin and adiponectin usin

100 Associations between cord blood concentrations of p,p -DDE and PCBs and sperm

101 e associations between maternal or umbilical cord blood concentrations of perfluorooctanoic acid and

102 anzanian birth cohort (n = 743), we measured cord blood concentrations of tumor necrosis factor (TNF)

103 n but is clinically relevant as maternal and cord blood cortisol levels are correlated and offspring

104 upplies are inadequate, allogeneic umbilical cord blood could be a feasible alternative.

105 cooperates with MA4 to initiate leukemia in cord blood-derived CD34(+) hematopoietic stem/progenitor

106 EV treatment of human umbilical cord blood-derived CD34(+) HSPCs alters the expression o

107 Comparison with expanded cord blood-derived CD4(+)CD25(hi) tTreg and expanded Tef

108 Human LAD2 cells and umbilical primary human cord blood-derived cultured mast cells were stimulated w

109 d TNF from LAD2 cells and of CCL2 from human cord blood-derived cultured MCs.

110 We examined the effects of human umbilical cord blood-derived ECFCs and their extracellular vesicle

111 studies indicate protective effects of human cord blood-derived ECFCs in experimental AKI and suggest

112 Cs, the endothelial layer consisted of human cord blood-derived endothelial progenitor cells (hCB-EPC

113 Umbilical cord blood-derived haematopoietic stem cells (HSCs) are

114 ator of adhesive properties in primary human cord blood-derived hematopoietic stem and progenitor cel

115 lts in a marked expansion of human umbilical cord blood-derived HSPCs following cytokine stimulation.

116 s prolong VEGFR-2 and Akt phosphorylation in cord blood-derived late outgrowth endothelial progenitor

117 Human cord blood-derived mast cells and the HMC-1 mast cell li

118 e of the type I interferon receptor on human cord blood-derived mast cells reduced the RSV-mediated i

119 Human cord blood-derived mast cells were treated for 2 weeks w

120 The LAD2 MC line or primary human cord blood-derived MCs (CBMCs) were infected with HRV or

121 nduction were similar to levels achieved for cord blood-derived MPP and up to 20-fold higher than tho

122 adoptive transfer of ex vivo expanded human cord blood-derived NK cells into humanized mice reconsti

123 llowed by independent validation of selected cord blood differentially methylated regions, using bisu

124 the association between gestational age and cord blood DNA methylation at birth and whether DNA meth

125 y levels were associated with lower regional cord blood DNA methylation at the Paraoxonase 1 gene (PO

126 ker measured mid-pregnancy, and Illumina450K cord blood DNA methylation from newborns in the Norwegia

127 sal effect of maternal vitamin B12 levels on cord blood DNA methylation using the maternal FUT2 genot

128 sal effect of maternal vitamin B12 levels on cord blood DNA methylation, and a causal effect of vitam

129 aternal prenatal blood mercury levels in 321 cord blood DNA samples and examined the persistence of t

130 of available self-Ag and the genetics of the cord blood donor dictate the levels of central tolerance

131 atopoietic-cell transplant from an unrelated cord-blood donor (140 patients), an HLA-matched unrelate

132 urvival after receipt of a transplant from a cord-blood donor was at least as favorable as that after

133 d be measured in spots of wild-type adult or cord blood dried onto filter paper at levels significant

134 The miR-193a-3p mimic reduced cord blood ECFC-derived cell proliferation, migration an

135 HMGB1 silencing in cord blood ECFC-derived cells confirmed its role in regu

136 reporter assays of miR-193a-3p mimic treated cord blood ECFC-derived cells, we identified 2 novel miR

137 cid intakes during pregnancy on maternal and cord blood folate concentrations have not been well esta

138 genome-wide DNA methylation in placenta and cord blood from 27 GDM exposed and 21 unexposed offsprin

139 m samples before and after immunisation, and cord blood from a subset of women and infants.

140 after vaccination and at both deliveries, in cord blood from both siblings, and in infants before and

141 bolism) were hypermethylated in placenta and cord blood from SGA newborns, whereas GPR120 (related to

142 n of a CXCR3 ligand, CXCL9, was increased in cord blood from SPTB, and the protective rs2280964 allel

143 ssociations between maternal urinary TCS and cord blood FT3 as well as maternal blood FT4 concentrati

144 Upon cord blood full chimerism, the patient's CCR5 Delta32 ho

145 t positive correlations between maternal and cord blood glucocorticoid levels, increased maternal BMI

146 d maternal BMI was not associated with lower cord blood glucocorticoid levels.

147 n the two unrelated-donor groups than in the cord-blood group (hazard ratio in the HLA-mismatched gro

148 gher in the HLA-mismatched group than in the cord-blood group (hazard ratio, 2.92; 95% confidence int

149 ative risks of death and relapse between the cord-blood group and the two other unrelated-donor group

150 higher in the HLA-matched group than in the cord-blood group but not significantly so (hazard ratio,

151 the probability of relapse was lower in the cord-blood group than in either of the other groups.

152 CD4+ and CD8+ T cells from cord blood, healthy young children, and adults were chal

153 Cord blood hematopoietic stem cells (CB-HSCs) are an out

154 re-compatible marker of UM171-expanded human cord blood HSCs.

155 ation of canonical AHR pathway components in cord blood HSPCs.

156 nduces B cell lymphomas in a newly developed cord blood-humanized mouse model that allows EBV-infecte

157 We recently used a newly developed cord blood-humanized mouse model to show that EBV can co

158 ity of EBV to induce B cell lymphomas in the cord blood-humanized mouse model, although the simultane

159 estigate the influence of season of birth on cord blood immune cell subsets and inflammatory mediator

160 season, and correlations between individual cord blood immune cells and early airway immune mediator

161 t and result in differential potentiation of cord blood immune cells and early airway mucosal immune

162 zed mice reconstituted with autologous human cord blood immune cells.

163 sed versus laboratory mice, and adult versus cord blood in humans.

164 Moreover, resting cord blood KIR3DL1 NK cells exhibited a basal alloreacti

165 ynamic diameter </=2.5 microm) and umbilical cord blood leptin and adiponectin levels with mixed-effe

166 as early as the second trimester with fetal cord blood leptin and stronger association beginning as

167 were seen between air pollution markers and cord blood leptin levels in models that adjusted for bir

168 with 8.8% (95% CI, -14.1% to -3.1%) shorter cord blood leukocyte telomeres and 13.2% (95% CI, -19.3%

169 Cord blood levels of free triiodothyronine (FT3), FT4, T

170 Fetal cord blood levels of sCD14, LBP, and IL-6 were determine

171 With adjustment for potential confounders, cord blood log(FT3)pmol/L concentration was 0.11 lower i

172 hat lympho-myeloid progenitor populations in cord blood - lymphoid-primed multi-potential progenitors

173 Geometric mean cord blood MeHg was 0.94 mug/L (95% CI: 0.84, 1.07).

174 teristics and further adjusted for umbilical cord blood mercury or long-chain polyunsaturated fatty a

175 25th-75th percentile) maternal and umbilical cord blood metal concentrations, respectively, were as f

176 lead, and manganese on cognitive score when cord blood metals concentrations were all above the 60th

177 Cord blood methylation at the PON1 locus predicted lower

178 In cord blood, methylation at 15 CpG sites in seven gene re

179 In cord blood, methylation at 224 CpG sites was found to be

180 ania, we evaluated the presence and level of cord blood MMc in offspring of women with and without PM

181 nd did not require coinjected T cells in the cord blood model.

182 rs expression on adult monocytes compared to cord blood monocytes, and that CD300c and CD300e-mediate

183 Cord blood mononuclear cell-derived IL-1beta levels were

184 very Assay chip to survey DNA methylation in cord blood mononuclear cells from 36 children (18 nonast

185 Here, we found that i.p. injection of human cord blood mononuclear cells infected with a LMP1-defici

186 imulation, and an enhanced IL-10 response of cord blood mononuclear cells to dexamethasone treatment

187 pectrum proinflammatory cytokine response of cord blood mononuclear cells to innate and mitogenic sti

188 ipheral blood mononuclear cells and neonatal cord blood mononuclear cells.

189 P was observed at 74% of placenta and 59% of cord blood MVPs.

190 n Rural Environments (PASTURE) birth cohort (cord blood [n = 836], 1 year [n = 734], 4.5 years [n = 7

191 erology on blood samples collected at birth (cord blood, n = 626) and at follow-up at 3 years (n = 81

192 ns (TORCH), Apgar score <5 at 5 min, sepsis, cord blood not collected, or auditory evaluation unable

193 epigenome-wide DNA methylation in umbilical cord blood nucleated cells in Project Viva, a prospectiv

194 We profiled DNA methylation in cord blood of 114 children selected from the lowest and

195 explored sex-specific DNA methylation in the cord blood of 39 females and 32 males born at term and w

196 (LOI) of IGF2 and H19 genes in placentas and cord blood of 90 mother-child dyads in association with

197 iate T cell suppression and are increased in cord blood of healthy newborns and in peripheral blood o

198 ns of adalimumab and infliximab in umbilical cord blood of newborns and rates of clearance after birt

199 Evidence from cord blood of newborns who progress to overt T1D suggest

200 201/IMP(58-66) Abs were also detected in the cord blood of newborns, indicating that HLA-A*0201/IMP(5

201 nsplant from a HLA-mismatched donor and from cord blood, older age, and duration of severe neutropeni

202 ffect of PGE2 on human adult stem cells from cord blood or adipose tissue, and the regulation of its

203 s for detection of multiple viruses included cord blood or HLA-mismatched HCT, myeloablative conditio

204 Other BMT options include unrelated cord blood or mismatched family donors.

205 minated PBDEs were often higher in umbilical cord blood or serum than in maternal samples (median cor

206 r most PFCs and lead (Pb), concentrations in cord blood or serum were generally equal to or lower tha

207 al and neonatal tissues (eg, amniotic fluid, cord blood, placenta, and brain).

208 rnal plasma (M2) as well as infant umbilical cord blood plasma (CB).

209 3 million typed volunteer donors and 645,646 cord blood products by 2012.

210 fety of infusion of non-HLA-matched expanded cord blood progenitor cells after administration of clof

211 the use of non-HLA-matched ex-vivo expanded cord blood progenitor cells to accelerate haemopoietic r

212 vitro generation of red cells from adult and cord blood progenitors do not yet provide a sustainable

213 source (n = 839; 84%); peripheral blood and cord blood progenitors were used in 73 (7%) and 88 (9%)

214 Banked, unrelated umbilical cord blood provides access to hematopoietic stem cell tr

215 In cord blood, qPCR, TESA-blot, and micromethod sensitiviti

216 CCR5 Delta32 homozygous cord blood reconstitution can successfully eliminate HIV

217 e ranges (IQR)] of manganese in maternal and cord blood, respectively, were 24.0 (19.5-29.7) and 43.1

218 were isolated from bone marrow and umbilical cord blood, respectively.

219 95% CI: 1.68, 1.82 mIU/L), respectively] and cord blood samples [11.91 mIU/L (95% CI: 6.67, 17.14 mIU

220 We collected maternal and umbilical cord blood samples at delivery from 622 mother-infant pa

221 icals in 77 maternal and 65 paired umbilical cord blood samples collected in San Francisco during 201

222 ecific gene expression of IGF2, but 32.4% of cord blood samples displayed LOI of IGF2 and 10.8% showe

223 Cord blood samples from 168,055 newborn infants were scr

224 trimesters of pregnancy by using a subset of cord blood samples from a randomized, double-blind, plac

225 cytometry of paired peripheral and umbilical cord blood samples from mothers and their neonates with

226 Cord blood samples from neonates born to mothers supplem

227 282 school-age children from whom umbilical cord blood samples had been obtained and analyzed for me

228 ng was performed with a subset of placentas, cord blood samples, and buccal samples collected during

229 Using cord blood samples, we correlate the adult frequency hie

230 ssessed in 376 paired maternal and umbilical cord blood samples.

231 ith PON1 expression in an independent set of cord blood samples.

232 Twenty cord-blood samples were examined for the presence of ecu

233 ing strategies, for immunostaining of BM and cord blood specimens to study human DC hematopoiesis in

234 R) for the presence of microorganisms, while cord blood specimens were analyzed for the presence of c

235 n tissue, chorioamnion tissue specimens, and cord blood specimens were obtained at delivery.

236 ntribute to inferior platelet recovery after cord blood stem cell transplantation and may underlie in

237 demonstrated dramatic expansion of umbilical cord blood stem cells that promote rapid engraftment whi

238 the percentage of circulating CD4(+) CD25(+) cord blood T cells was independent of birth order.

239 Purified cord blood T cells were polyclonally activated with anti

240 helper T cells (P = 0.0003) in the activated cord blood T cells were selectively reduced in first-bor

241 er and the functional response of stimulated cord blood T cells.

242 o 4-fold higher levels of circulating EDA in cord blood than in adult sera.

243 tem and progenitor cells isolated from human cord blood that may better recapitulate the behavior of

244 as heterozygous for H19 and 37 placentas and cord blood tissues heterozygous for IGF2 and H19 methyla

245 on, analyzing samples ranging from umbilical cord blood to centenarian peripheral blood.

246 The median ratio of maraviroc cord blood to maternal blood was 0.33 (range, 0.03-0.56)

247 ts to be probably or certainly caused by the cord blood transfusion (one-sided 97.5% CI 0-6.5).

248 udy was to assess the safety and efficacy of cord blood transfusion in children with severe anaemia.

249 significantly more frequent after umbilical cord blood transplant and was associated with an increas

250 the curve (AUC) of ATG after infusion of the cord blood transplant predicted successful CD4(+) IR.

251 Cord blood transplant slows disease progression much mor

252 While cord blood transplantation (CBT) is an effective therapy

253 The ability of cord blood transplantation (CBT) to prevent relapse depe

254 Delayed engraftment is a major limitation of cord blood transplantation (CBT), due in part to a defec

255 d with improved outcomes following pediatric cord blood transplantation (CBT).

256 eneic cell transplantation [ACT]; n = 18) or cord blood transplantation (CBT; n = 16).

257 Although double umbilical cord blood transplantation (dUCBT) in adult patients may

258 reactivity is favored after double umbilical cord blood transplantation (dUCBT) in which cord blood (

259 HHV-6B) commonly reactivates after umbilical cord blood transplantation (UCBT) and is associated with

260 (n = 226) or double-unit (n = 435) unrelated cord blood transplantation (UCBT) following a reduced-in

261 atching who received a single unit umbilical cord blood transplantation for non-malignant diseases re

262 Although cord blood transplantation has significantly extended th

263 CD34(+)/CD38(-)/CD90(+)/CD45RA(+) HSCs after cord blood transplantation.

264 leted bone marrow or unmanipulated umbilical cord blood transplantation.

265 ion for non-malignant diseases-for umbilical cord blood transplantation.

266 immune response on outcomes after unrelated cord blood transplantations (CBTs).

267 GRFS after umbilical cord blood transplants and marrow from matched unrelated

268 iving combination haploidentical single-unit cord blood transplants, we have added 4 Gy TBI to the wi

269 rtoire is private and initially unfocused in cord blood, typically becoming strongly focused on a few

270 Clinical application of umbilical cord blood (UCB) as a source of hematopoietic stem cells

271 Umbilical cord blood (UCB) engraftment is in part limited by graft

272 Umbilical cord blood (UCB) is a promising source of stem cells to

273 ge as to whether FLG expression in umbilical cord blood (UCB) is associated with eczema development a

274 We recently reported that umbilical cord blood (UCB) monocytes from babies born to obese mot

275 to improve engraftment after donor unrelated cord blood (UCB) transplantation in adults.

276 cord blood transplantation (dUCBT) in which cord blood (UCB) units and patients are often HLA class

277 Transplantation of 2 unrelated cord blood (UCB) units instead of 1 has been proposed to

278 outcomes of patients treated with umbilical cord blood (UCB)-derived regulatory T cells (Tregs) that

279 We evaluated the impact of recipient and cord blood unit (CBU) genetic polymorphisms related to i

280 recovery generally originates from a single cord blood unit (CBU).

281 part, to inadequate potency of the selected cord blood unit (CBU).

282 e standard for selecting unrelated umbilical cord blood units for transplantation for non-malignant d

283 ice in that selection of unrelated umbilical cord blood units for transplantation for non-malignant d

284 Metals were measured in cord blood using inductively coupled plasma-mass spectro

285 race, mode of delivery, breast-feeding, and cord blood vitamin D levels are associated with infant g

286 Cord blood vitamin D was linked to increased Lachnobacte

287 Umbilical cord blood was analyzed for speciated mercury, serum ome

288 Cord blood was phenotyped for 26 different immune cell s

289 Of the 87 children eligible for the study, cord blood was unavailable for 24, six caregivers declin

290 Using human cord blood, we show that the common TT risk genotype (R2

291 At birth, maternal and cord blood were collected for chemical analyses, and inf

292 Additionally, BPA and TNF-alpha levels in cord blood were inversely associated with maternal and G

293 matopoietic stem cell progenitors from human cord blood were subjected to both inhibition and overexp

294 stem cell transplantation, frozen samples of cord blood were thawed and the purity of viable nucleate

295 umber of activated and regulatory T cells in cord blood whereas it was independent of concomitant pre

296 of nonsense-mediated mRNA decay in umbilical cord blood, which may reflect specific regulatory mechan

297 needed to compare the safety and efficacy of cord blood with conventional adult-donated blood for tra

298 tion differences) in normal somatic tissues (cord blood) with both a prenatal exposure (conception in

299 ed in human serum as well as in maternal and cord blood within 30s.

300 In naive Th cells from cord blood, ZBTB16 expression was confined to CD161(+) c